Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 6946-6951

  Manjarrez, María E ^a   Ocadiz, Rodolfo ^b   Valle, Leticia ^a   Pacheco, Cesar ^b   Marroquin, Alberto ^b   De La Torre, Carlos ^c   Selman, Moisés ^a   Gariglio, Patricio ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; PROTEIN PRB; TUMOR SUPPRESSOR PROTEIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; LARYNX PAPILLOMATOSIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PAPILLOMA; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845783788     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1214     Document Type: Article

References (47)

1. Hyams VJ, Heffner DK. Laryngeal pathology. In: Tucker HM, editor. The Larinx. New York: Thieme Medical Publishers, Inc.; 1993. p. 35-80.
2. Uobe K, Masuno K, Fang YR, et al. Detection of HPV in Japanese and Chinese oral carcinomas by in situ PCR. Oral Oncol 2001;37:146-52.
3. Miller CS, Johnstone BWI. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622-35.
4. Poetker DM, Sandler AD, Scott DL, Smith RJ, Bauman NM. Survivin expression in juvenile-onset recurrent respiratory papillomatosls. Ann Otol Rhinol Laryngol 2002;111:957-61.
5. Rabah R, Sakr W, Thomas R, Lancaster WD, Gregoire L. Human papillomavirus type, proliferative activity, and p53. Arch Pathol Lab Med 2000;124:721-4.
6. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 1983;80:560-3.
7. Moore C, Wiatrak BJ, McClatchey KD, et al. High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas. Otolaryngol Head Neck Surg 1999;120:698-705.
8. Go C, Schwartz MR, Donovan DT. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 2003;112:298-302.
9. Rady PL, Schnadig VJ, Weiss RL, Hughes TK, Tyring SK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope 1998;108:735-40.
10. Münger K, Baldwin A, Edwards EM, Hayakawa H. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-60.
11. Schmitt A, Harry JB, Rapp B, Wettstein FO, Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J Virol 1994;68:7051-9.
12. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO 1989;8:4099-105.
13. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-78.
14. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
15. Nguyen MI, Nguyen MM, Lee D, Griep AE, Lambert PF. The PDZ ligand domain on the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 2002;77:6957-64.
16. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245-6.
17. Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene 2002;21:8223-31.
18. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1-10.
19. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
20. Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat 1999; 54:39-45.
21. Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Bax and Bcl-2 protein expression in gastric pre-cancerous lesions: immunohistochemical study. J Gastroenterol Hepatol 2005;20:1674-8.
22. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Jr., Ross JS. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004;128:39-43.
23. Choi J, Choi K, Benveniste EN, et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005;65:5554-60.
24. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991;82:524-31.
25. Nuovo GJ. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 1997;71:1056-60.
26. Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol 1991;72:1039-44.
27. Storey A, Osborn K, Crawford L. Co-transformation by human papillomavirus types 6 and 11. J Gen Virol 1990;71:165-71.
28. Gupta S, Takhar PP, Degenkolbe R, et al. The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology 2003;317:155-64.
29. Abramson AL, Nouri M, Mullooly V, Fisch G, Steinberg BM. Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004;72:473-7.
30. Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11- associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001;4:68-72.
31. Reidy PM, Dedo HH, Rabah R, et al. Integration of papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope 2004; 114:1906-9.
32. Turraza E, Lapena A, Sprovieri O, et al. Low-risk human papillomavirus types 6 and 11 associated with carcinomas of the genital and upper aero-digestive tract. Acta Obstet Gynecol Scand 1997;76:271-6.
33. Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E/proteins in the life cycle of low-risk human papillomavirus type 11. J Virol 2004;78:2620-6.
34. Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996; 70:4509-16.
35. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
36. Lavia P, Mileo AM, Giordano A, Paggi MG. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene 2003;22:6508-16.
37. Li DK, Adler-Storthz K, Follen M, Clayman GL, Chen Z. Expression of human papillomavirus E7 mRNA in human oral and cervical neoplasia and cell lines. Oral Oncol 1999;35:415-20.
38. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003;14:191-6.
39. Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992;70:337-50.
40. Salcedo M, Taja L, Utrera D, et al. Changes in retinoblastoma gene expression during cervical cancer progression. Int J Exp Pathol 2002;83:275-85.
41. Wang HL, Lu DW. Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol 2004;28:901-8.
42. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
43. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 2001; 21:7653-62.
44. Evan GL, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
45. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:745-6.
46. 1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression. Leukemia 2005;19:1051-7.
47. Cotter FE. Unraveling biologic therapy for Bcl-2-expressing malignancies. Semin Oncol 2004;31: 18-21.